Article | November 10, 2022

How To Avoid Warning Letters For Data Integrity Nonconformances In Life Sciences

By David Jensen, Staff Writer, MasterControl

medical data iStock-1250153388.jpg

In 2018, the U.S. Food and Drug Administration (FDA) published its final guidance detailing how companies developing regulated products need to maintain and ensure the integrity of their data throughout the product’s life cycle. The bottom line is the FDA expects that all data be complete, reliable, accurate, and consistent. Data integrity is established where the data is stored and managed in its original form.

To be confident that no corners were cut or data was falsified in product development, the FDA expects manufacturers to ensure all data meets the guidelines outlined in the ALCOA acronym:

  • Attributable - Easily identified to the person who collected the data, the data’s place of origin, and the time the data was collected.
  • Legible - Data should be easily read for as long as the data exists.
  • Contemporaneously recorded or a true copy - The date and time the data was collected should
  • Original - The original data records need to be preserved throughout their life cycle, meaning the data storage processes and materials need to be durable.
  • Accurate - Data needs to be error free and high quality. All changes must include supporting documentation.1

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online